Login to Your Account



Schering-Plough To Make 20-mg Dose

Santarus Gets As Much As $80M In OTC Zegerid Deal

By Randall Osborne


Monday, October 23, 2006
Faced with a need for non-dilutive cash, Santarus Inc. found relief in Schering-Plough Corp.'s agreement to pay as much as $80 million for rights to an over-the-counter, lower-dose version of Zegerid (omeprazole) for heartburn-related indications. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription